Valeant Deal a Good Thing for Billionaire Investors

Valeant Deal a Good Thing for Billionaire Investors

Valeant, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) and Enzymotec Ltd. (NASDAQ:ENZY) are approaching market close with noteworthy gains this Monday. Voltari Corp. (NASDAQ:VLTC), Cobalt International Energy Inc. (NYSE:CIE) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), on the other hand, are starting off the week in the red.

Sign up for our free newsletter

David Einhorn At The 2021 Sohn Investment Conference: Buy These Copper Plays

david einhorn, reading, valuewalk, internet, investment research, Greenlight Capital, hedge funds, Greenlight Masters, famous hedge fund owners, big value investors, websites, books, reading financials, investment analysis, shortselling, investment conferences, shorting, short biasThere's a gold rush coming as electric vehicle manufacturers fight for market share, proclaimed David Einhorn at this year's 2021 Sohn Investment Conference. Check out our coverage of the 2021 Sohn Investment Conference here. Q1 2021 hedge fund letters, conferences and more SORRY! This content is exclusively for paying members. SIGN UP HERE If you Read More


Valeant Acquisition Deal a Boost to Paulson, Billionaires


Valeant Pharmaceuticals surged +14.04% today after news broke over the weekend that it has agreed to buy Salix Pharmaceuticals in a $10 billion deal. Billionaire shareholder John Paulson is pleased with the deal, his hedge fund calling the agreement “very accretive to Valeant.” Steve Mandel, Jorge Lemann and George Soros stand to profit as well (the stock is quite a billionaire favorite).

Bellicum Pharmaceuticals Inc. climbed +11.35%, though YTD the biotech stock remains flat. George Soros picked up 27,000 BLCM shares during the fourth quarter of 2014.

Enzymotec gained +9.49% and is up more than +35% over the past five days. Another John Paulson bet, the company reported fourth quarter numbers last week, including a $1.1 million profit.

Cobalt Tumbles After Reporting Q4 Loss

Voltari Corp. tumbled -8.06%, putting its one-month loss at nearly -25%. Carl Icahn picked up a stake in the firm during the second quarter of 2013 and, despite the stock’s underperformance, has held on since.

Cobalt International Energy fell -6.32% after reporting a net loss of $216.6 million in its fourth quarter results. The exploration and production company, a John Paulson holding, has declined more than -50% over the past year.

The share price of Vanda Pharmaceuticals dipped -5.95% today and has declined about -25% this year. Last week, Jeffries Group dropped its price target on the stock from $33.00 to $30.00. John Paulson first bought into the company during the first quarter of 2014 and as of the last quarter of the year holds 3.63 million VNDA shares.

Screen Shot 2015-02-23 at 3.00.26 PM


No posts to display